Adelaide, Australia/San Diego, USA – Avance Clinical, the leading Australian-based biotech CRO with US operations will sponsor and present the China BioPharma Award at the global biotech Scrip Awards in London next month.
Avance Clinical congratulates the China BioPharma Award shortlisted companies:
- Anticancer Bioscience
- BeiGene China
- Brii Biosciences
- Clover Biopharmaceuticals
- Everest Medicines
Avance Clinical CEO Yvonne Lungershausen will present the award at the official ceremony on 30 November 2022. Avance Clinical’s Global Head of Business Development Liahna Toy will also attend the event which brings together more than 400 biotech companies.
Discussing the China BioPharma Award Yvonne Lungershausen said:
“With more than 20% of our biotech clients coming from China, we are sponsoring this award to shine a global spotlight on the calibre of innovation we see first-hand from the region.
Many of Avance Clinical’s biotech China clients are planning FDA approval in North America. Working with Avance Clinical, our clients execute on that strategy by starting their drug development program in Australia and pivoting to North America for greater site and patient access in later phase trials. These clients are already benefiting from Avance Clinical’s recent expansion into North America and the new GlobalReady service which enables them to work seamlessly with our data and project teams across all phases and regions.
Avance Clinical’s Australian operations offers clients the opportunity to maximise on significant rebates of up to 43.5%, expedited approvals, and world-class trial data for their early phase clinical development. Our GlobalReady service supports biotechs’ progress through later phases in North America for FDA approvals.
We have shown, with our high growth and industry-leading repeat business rates that our focus on gold-standard technology paired with solution-orientated clinical experts is the mix our biopharma clients need for clinical success.”
Now in its 18th year, the Scrip Awards brings together industry leaders to celebrate and recognise the very best innovations and achievements in global biopharma. Winners will be celebrated across 15 categories.
Avance Clinical is the leading Australian-based biotech CRO with US operations providing global regulatory standard clinical research services across all phases for the international biopharma industry.
The company has a global reputation for agile clinical solutions to support accelerated clinical development for international biotech clients.
Avance Clinical is also accredited as a gene technology CRO under the Office of the Gene Technology Regulator (OGTR) for vaccines and GMO therapies clinical trials.
Avance Clinical has been recognised for the past two consecutive years with the prestigious Frost & Sullivan CRO Best Practices Award.
Find out more:
- Learn about the Australian Advantage here https://avancecro.121group.dev/the-australian-advantage/
- Read more about Avance Clinical’s cell and gene therapy capabilities here www.avancecro.com/avance-clinical-featured-in-endpoints-news-on-cell-gene-therapy-capabilities/
- For more information about the benefits of running your next study with Avance Clinical contact us: firstname.lastname@example.org
About Avance Clinical
Avance Clinical is the largest premium full-service Australian and US CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand and the US for international biotechs. The company’s clients are biotechs in their early phases of drug development that need fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past two years, has been providing CRO services in the region for more than 24 years.
Pre-clinical through to Phase 1 and 2
Avance Clinical offers pre-clinical services with their experienced ClinicReady team right through to Phase 1 and 2 clinical services leveraging significant Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.
With experience across more than 110 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, IBM Watson and Medrio are just some of the technology partners.